While partnering activities reached new highs in 2020, Chinese biopharma players found it more difficult to snatch good deals in a more competitive landscape. They now need to act faster and do more preparation work to seize partnering opportunities, panelists said at the Chinabio Partnering Forum.

Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.

Since joining the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use in 2017, China has approved clinical trials and marketing of drugs a lot faster with simultaneous clinical development at home and abroad.

To encourage more innovative medical devices to enter the market faster, China has revised its regulation to allow third parties to manufacture devices, foreign devices that are not yet approved overseas to be imported to the country, and to shorten the regulatory process. The new regulation will take effect on June 1. The 2021 version of the Regulation on Supervision and Administration of Medical Devices introduced a few important changes, echoing Beijing’s call to spur health care innovation. The last update was in 2014.